| __timestamp | HUTCHMED (China) Limited | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 79383000 |
| Thursday, January 1, 2015 | 29829000 | 108402000 |
| Friday, January 1, 2016 | 39578000 | 46928000 |
| Sunday, January 1, 2017 | 43277000 | 74959000 |
| Monday, January 1, 2018 | 48645000 | 79716000 |
| Tuesday, January 1, 2019 | 52934000 | 74669000 |
| Wednesday, January 1, 2020 | 61349000 | 59040000 |
| Friday, January 1, 2021 | 127125000 | 77417000 |
| Saturday, January 1, 2022 | 136106000 | 91473000 |
| Sunday, January 1, 2023 | 133175999 | 94314000 |
Unleashing insights
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. HUTCHMED (China) Limited and MannKind Corporation, two prominent companies, have exhibited distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, HUTCHMED's SG&A expenses surged by nearly 400%, peaking in 2022. This growth reflects their aggressive expansion and investment in administrative capabilities. In contrast, MannKind's SG&A expenses have remained relatively stable, with a modest increase of about 19% over the same period. This stability suggests a more conservative approach, focusing on maintaining operational efficiency.
These contrasting strategies highlight the diverse paths companies can take in managing their operational costs, offering valuable insights for investors and industry analysts alike.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and MannKind Corporation
Comparing SG&A Expenses: Zoetis Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Who Optimizes SG&A Costs Better? ACADIA Pharmaceuticals Inc. or MannKind Corporation
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.